Biomedicines (Jul 2022)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

  • Giammarco Mocci,
  • Giorgia Bodini,
  • Leonardo Allegretta,
  • Alessia Immacolata Cazzato,
  • Stefania Chiri,
  • Giovanni Aragona,
  • Patrizia Perazzo,
  • Antonio Ferronato,
  • Maria Giovanna Graziani,
  • Cristiano Pagnini,
  • Costantino Zampaletta,
  • Camilla Graziosi,
  • Marcello Picchio,
  • Walter Elisei,
  • Giovanni Maconi,
  • Antonio Tursi

DOI
https://doi.org/10.3390/biomedicines10081799
Journal volume & issue
Vol. 10, no. 8
p. 1799

Abstract

Read online

The approval of adalimumab (ADA) biosimilars for inflammatory bowel disease (IBD) has reduced the cost of treatment. While several ADA biosimilars are currently available, comparative data on the ADA biosimilar GP2017 (HyrimozTM) and its originator (HumiraTM) in IBD are lacking. We compared the efficacy and safety of GP2017 versus originator in IBD outpatients in an Italian real-life setting. This retrospective analysis enrolled consecutive IBD patients with complete clinical, laboratory, and endoscopic data. Clinical activity was assessed with the Mayo score in ulcerative colitis (UC) and the Harvey–Bradshaw Index in Crohn’s disease (CD). The primary endpoints were the induction of remission and the safety of GP2017 versus ADA originator. One hundred and thirty-four patients (30.6% with UC and 69.4% with CD, median age 38 years) were enrolled: 62 (46.3%) patients were treated with GP2017, and 72 (53.7%) with ADA originator; 118 (88.1%) patients were naïve to ADA. Clinical remission was obtained in 105 (78.4%) patients, during a median follow-up of 12 months, 82.3% and 75% in the GP2017 and ADA originator groups, respectively (p = 0.311). Treatment was well tolerated in both groups. This analysis of real-world data suggests that GP2017 and its originator are equivalent in terms of efficacy and safety in patients with IBD.

Keywords